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Abstract 34 
Background:   Although IgA is the most abundantly produced immunoglobulin, its role 35 
in preventing HIV-1 acquisition, which occurs mostly via mucosal routes, remains 36 
unclear.  Data from the RV144 trial implied that vaccine-induced plasma IgA antibodies 37 
(Abs) counteracted the protective effector mechanisms of IgG1 Abs with the same 38 
epitope specificity; mucosal samples were not available for study.  We previously 39 
performed passive mucosal immunizations in rhesus macaques (RMs) with the HIV-1 40 
envelope (Env)-specific, neutralizing monoclonal antibody (mAb) HGN194.  The dimeric 41 
IgA2 (dIgA2) form of the mAb administered intrarectally (i.r.) protected only 17% of the 42 
RMs, whereas the dimeric IgA1 (dIgA1) version also given i.r. prevented infection in 43 
83% of the macaques after i.r. challenge with simian-human immunodeficiency virus 44 
(SHIV).  We hypothesized that mucosal dIgA2 might diminish the protection provided by 45 
IgG1 mAbs targeting the same epitope.   46 
Results:  To test our hypothesis, we compared intravenously (i.v.) administered 47 
HGN194 IgG1 either alone or in combination with the dIgA2 version given i.r..  Both 48 
mAb forms used as single agents and the combination of the two neutralized the 49 
challenge virus equally well in vitro.  None of the RMs given i.v. HGN194 IgG1 alone 50 
remained virus-free.  In contrast, all RMs given the HGN194 IgG1+dIgA2 combination 51 
were completely protected against high-dose i.r. SHIV-1157ipEL-p challenge. 52 
Conclusion:  Combining suboptimal defenses at the mucosal and systemic levels can 53 
completely prevent virus acquisition in all animals.  These data imply that active 54 
vaccination should focus on defense-in-depth, a strategy that seeks to build up fortified 55 
defensive fall-back positions well behind the armed frontline.    56 
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Background 62 
The partially successful RV144 trial has opened new horizons for HIV-1 vaccine design 63 
while posing new challenges for researchers [1].  Post-trial analyses revealed an 64 
inverse correlation between IgG antibodies (Abs) specific for the variable loops 1 and 2 65 
(V1V2) of the HIV-1 envelope (Env) and the risk of HIV-1 infection.  A direct correlation 66 
between plasma Env-specific IgA and the risk of HIV-1 infection was also observed [2], 67 
although vaccinees with high Env-specific plasma IgA were not more likely to become 68 
infected than placebo recipients.  Additionally, antibody-dependent cellular cytotoxicity 69 
(ADCC) responses in the presence of low plasma concentration of anti-Env IgA 70 
correlated with reduced risk of infection. These findings suggested that Env-specific 71 
circulating IgA impeded the protective effects of IgG Abs.  Secondary analyses showed 72 
that vaccinees with plasma IgA specific to the first conserved region (C1) of HIV-1 Env 73 
gp120 had a higher risk of infection than vaccinees without C1-specific IgAs [2].  C1-74 
specific monoclonal Abs (mAbs) isolated from RV144 vaccinees and expressed as IgG1 75 
showed HIV-1-specific ADCC-mediated cell killing [3].  Of note, two of these ADCC-76 
mediating IgG1 mAbs, namely CH29 and CH38, were originally of IgA2 and IgA1 77 
isotypes, respectively.  Later, Tomaras et al. demonstrated that the C1 epitope 78 
recognized by total plasma IgA and mAbs CH29 and CH38 expressed as IgA2 79 
overlapped with the epitopes of IgG1 mAbs within the same Env region [4].  80 
Remarkably, mAb CH38 expressed as IgA2 (originally IgA1) inhibited ADCC activity of 81 
C1-specific IgG1 mAbs isolated from RV144 vaccinees, while mAb CH29 expressed as 82 
IgA2 (originally IgA2) did not [4].  Since mucosal samples had not been collected during 83 
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the RV144 trial, the question remains as to how IgA2 and IgG1 with the same epitope 84 
specificity would interact in the mucosal compartment.  85 
Most existing vaccines are administered intramuscularly or subcutaneously and 86 
induce both systemic IgG and IgA antibody responses.  However, robust mucosal IgA 87 
responses with such vaccines are rarely generated [reviewed in [5]].  In contrast, 88 
intranasal and oral vaccination strategies induce strong mucosal IgA as well as serum 89 
IgG responses and have been successfully implemented against the number of 90 
infectious agents [reviewed in [5, 6]].  Mucosal immunization of rhesus monkeys (RMs) 91 
with HIV or SIV antigens led to the development of specific IgA responses in vaginal 92 
and rectal fluids [7-9].  RMs immunized via both the intramuscular and intranasal routes 93 
with HIV-1 gp41-subunit antigens grafted on virosomes were completely protected from 94 
persistent systemic infection with SHIV-SF162P3 and showed gp41-specific vaginal 95 
transcytosis-blocking IgAs as well as vaginal IgGs with neutralizing and/or antibody-96 
dependent cellular-cytotoxicity activities [10].  97 
IgA is the most abundant immunoglobulin (Ig) class: each day, the human body 98 
generates more IgA than all other Ig classes combined [reviewed in [11]].  IgA is mostly 99 
produced in lymphoid tissues associated with mucosal surfaces; IgA production in the 100 
gut amounts to 40–60 mg kg-1 day-1 [reviewed in [12]].  Humans have two IgA isotypes – 101 
IgA1 and IgA2 – and both are presented as dimers or polymers at mucosal sites.  HIV-1 102 
Env-specific IgA1 has been found in cervicovaginal secretions of highly exposed 103 
persistently seronegative (HEPS) women [13, 14].  Moreover, HEPS men who had sex 104 
with men developed serum IgA1 recognizing HIV-1 Env after oral exposure to HIV-1 105 
[15] and HIV-1-specific IgA was found in cervicovaginal fluids of repeatedly exposed sex 106 
 7 
workers [16, 17].  Furthermore, mucosal IgA Abs specific to HIV-1 gp41 were 107 
associated with protection against HIV-1 infection in seronegative partners of HIV-1-108 
infected individuals [18]. 109 
The RM/primate immunodeficiency virus model is widely used for HIV-1 vaccine 110 
research to reflect vaccination of HIV-1-naïve individuals.  However, it is likely that most 111 
people are exposed to live HIV-1 without becoming systemically infected.  Thus, the 112 
ability of the naïve RM model to predict possible outcomes in live-HIV-experienced 113 
humans is unknown.  In this regard, a non-human primate model using simian-human 114 
immunodeficiency virus (SHIV)-exposed but uninfected macaques will reflect the real-115 
life situation where prospective recipients of an AIDS vaccine are not naïve but have a 116 
history of HIV-1 exposure that did not result in seroconversion.   117 
In our recent RM study, passive intrarectal (i.r.) immunization with a dimeric IgA1 118 
(dIgA1) version of the anti-V3 loop crown mAb, HGN194 [19], completely protected five 119 
out of six RMs against i.r. SHIV challenge [20].  In contrast, the dIgA2 form of the same 120 
mAb protected only one out of six RMs.  In the same study, the IgG1 version of 121 
HGN194 given i.r. prevented infection in two out of six passively immunized animals. 122 
The proposed mechanism of differential protection was better virion capture by dIgA1 123 
compared with dIgA2 due to the longer hinge region of dIgA1.   124 
It is worth mentioning that the ratio of IgA1 and IgA2 varies in different human 125 
mucosal fluids, with IgA1 percentages in male genital secretions and nasal fluids 126 
reaching 80-90% and 60% in saliva. Female genital secretions and rectal fluids contain 127 
approximately 60% IgA2 [reviewed in [21]].  Among primates, only some great apes 128 
have two IgA isotypes, and all macaques, including RMs, possess only one IgA version, 129 
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which is structurally similar to human IgA2 [22].  In this regard, assessing the 130 
relationship between mucosal IgA2 and systemic IgG with the same epitope specificity 131 
and elucidating the role of this combination against immunodeficiency virus acquisition 132 
is important and timely.  133 
The potentially negative role of IgA responses in the RV144 trial mentioned 134 
above led us to hypothesize that mucosal dimeric IgA2 could compromise the protective 135 
effect of IgG1 of the same epitope specificity.   Here, we present the results of a study 136 
using systemic infusion of IgG1 and i.r. application of dIgA2 mAbs with the same 137 
epitope specificity performed in RMs that had been previously exposed to SHIV but 138 
remained aviremic and seronegative.  Unexpectedly, all RMs treated with the 139 
combination of HGN194 IgG1+dIgA2 were completely protected against mucosal SHIV 140 
challenge. 141 
 142 
Results 143 
Animal selection and analysis of immune responses 144 
The current study used RMs that had remained aviremic and seronegative during two 145 
separate, earlier experiments involving passive immunization with mAb HGN194 146 
followed by i.r. SHIV challenge.  The human IgG1 neutralizing mAb (nmAb) HGN194, 147 
isolated from a long-term non-progressor infected with HIV-1 clade AG, targets the V3-148 
loop crown and protects against cross-clade SHIV challenge in vivo [19, 23].  The use of 149 
previously exposed animals recapitulates the common scenario in humans, where any 150 
given HIV-1 exposure results in a low incidence of systemic infection and where non-151 
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transmitting exposures result in local and systemic immune responses in some 152 
individuals. 153 
The first study involved topical (i.r.) application of HGN194 dIgA1, dIgA2 or IgG1 154 
[20].  A second, unpublished experiment sought to elucidate the role of nmAb effector 155 
functions in protection agaisnt i.r. SHIV challenge.  In this second study, RMs had been 156 
treated intravenously (i.v.) with wild-type HGN194 IgG1 (IgG1wt), its LALA mutant 157 
(IgG1LALA) in which binding to the Fcγ receptor (FcγR) was abrogated thereby deleting 158 
effector functions, or with an afucosylated version (IgG1kif) of HGN194 IgG1 that had 159 
increased binding to FcγRIII, respectively (unpublished data).  In both studies, the 160 
macaques had been challenged i.r. with 31.5 50% animal infectious doses (AID50) of the 161 
R5 clade C SHIV-1157ipEL-p [24].   162 
All RMs selected for the current study were persistently aviremic (as measured 163 
by a sensitive RT-PCR assay [25]) and were seronegative by SIV Gag ELISA (data not 164 
shown).  We assessed preselected animals for cellular and humoral immune responses 165 
to viral proteins.  SIV Gag-specific proliferative CD4+ and CD8+ T-cell responses were 166 
measured at four to eight weeks after the earlier viral challenge (Figure 1).  Although 167 
persistently aviremic, 9 out of 14 macaques had measurable proliferation of CD4+ cells 168 
and 11 animals showed CD8+ proliferation in responses to stimulation with SIV Gag 169 
peptides; three RMs had marginal responses and animal RBk-14 showed no reaction.  170 
In general, proliferation of CD8+ cells was weaker than CD4+ lymphocytes.   171 
To analyze possible humoral immune responses among the preselected RMs, 172 
we first analyzed the residual plasma concentration of HGN194 IgG1 in all animals that 173 
had received the HGN194 mAbs systemically in a previous, unpublished study (Figure 174 
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2A).  At week 8 after the mAb passive transfer and virus challenge, the concentration of 175 
HGN194 IgG1wt was about 2 µg/ml and the IgG1kif concentration was marginally above 176 
background.  Four weeks later, IgG1wt was detected as low as at 0.14, 0.07 and 0.08 177 
µg/ml in the plasma of RMs RBk-14, REo-14, and RIk-14, respectively.  At the same 178 
time, the mAb concentration in the plasma of HGN194 IgG1kif -treated macaques fell 179 
below the detection limit.  Of note, the average in vivo 90% plasma inhibitory 180 
concentration (IC90) of HGN194 IgG1 was estimated at 2.15 µg/ml [23].  To allow 181 
complete clearance of previously infused mAbs, the current experiment was scheduled 182 
at 16 - 18 weeks after the initial mAb administration.  Additionally, we tested plasma 183 
samples of animals RBk-14, REo-14 and RIk-14 collected on the day of new mAb 184 
administration for any remaining HGN194 IgG1.  As expected, no mAb was detected 185 
just before re-administration (not shown).   186 
Next, we analyzed the RMs that had received the human mAbs HGN194 IgG1wt 187 
and IgG1kif systemically for possible anti-human IgG antibody responses.  During 188 
recurrent administrations of human IgG, these anti-species Abs, if developed, might 189 
cause adverse reactions and rapid elimination of human mAbs from the circulation.  190 
Importantly, none of the HGN194-treated RMs had developed any RM anti-human IgG 191 
Ab responses (Figure 2B) as a consequence of their prior treatment with HGN194 IgG1. 192 
Using ELISA, we next confirmed that the passively immunized, protected RMs 193 
had not mounted any anti-HIV-1 Env Ab responses of their own (Figures 2C and D). 194 
The secondary Ab in the ELISA was specific for RM IgGs only.  No reactivity was seen, 195 
as expected from the negative SIV Gag ELISA data (not shown).  Thus, the animals did 196 
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not have any Ab responses that may have skewed the new passive immunization/SHIV 197 
challenge study.   198 
 199 
Group assignment and study design 200 
Animals that had earlier received different versions of HGN194 mAb through different 201 
routes were distributed evenly between two new experimental groups (Table 1).  Each 202 
group contained two RMs that had received HGN194 IgG1 systemically and four RMs 203 
treated topically.  The control group consisted of two macaques that had received 204 
HGN194 IgG1 systemically.  MHC alleles and TRIM5α genotypes also were distributed 205 
evenly among the new groups (Table 1).  206 
The experimental timeline of the current study is depicted in Figure 3.  RMs in 207 
both Groups A and B received HGN194 IgG1 i.v. at 1.45 mg/kg 24 h before the viral 208 
challenge.  RMs of Group A were additionally treated with 1.25 mg of HGN194 dIgA2 209 
applied i.r. (1.25 mg of mAb in 2.1 ml of phosphate-buffered saline (PBS)) 30 min before 210 
the virus challenge.  Control Group C macaques were left untreated.  All animals were 211 
challenged i.r. with 31.5 AID50 of SHIV-1157ipEL-p [24], an R5 clade C SHIV, and 212 
monitored prospectively by measuring of plasma viral RNA (vRNA) loads. 213 
 214 
The combination of IgG1+dIgA2 versions of HGN194 completely protects RMs 215 
from single high-dose SHIV challenge 216 
The single mucosal high-dose challenge with SHIV-1157ipEL-p resulted in systemic 217 
infection of all macaques of Group B (HGN194 IgG1 only) by week 3 (Figure 4A).  218 
Control animals (Group C) were viremic as well.  Surprisingly, all Group A RMs, which 219 
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had received the combination of IgG1+dIgA2, remained aviremic.  The time to vRNA 220 
load >50 copies/ml for Groups A and B animals was compared by Kaplan-Meier 221 
analysis using the log-rank test with two-sided P-values (Figure 4B).  The combination 222 
of IgG1+dIgA2 demonstrated significantly better protection against mucosal SHIV-223 
1157ipEL-p challenge compared with IgG1 alone (P = 0.0005).  The shorter half-life of 224 
IgG1 in Group B RMs can be explained by absorption and removal of IgG1 from the 225 
circulation by newly replicating virus. 226 
In our previous experiment, the same virus challenge caused systemic infection 227 
of five out six RM treated with the same dose of dIgA2 i.r. [20].  The results of another, 228 
yet unpublished study with different IgG1 versions of HGN194 demonstrated infection of 229 
four out seven macaques infused i.v. with 1 mg/kg of IgG1wt.  Taken together, these 230 
results indicate that the combination of systemic IgG1 and topical dIgA2 treatments 231 
yielded better protection compared with individual mAb treatment alone.  232 
 233 
HGN194 IgG1 pharmacokinetics and plasma neutralization capacity 234 
The IgG1 pharmacokinetics were analyzed by ELISA.  The infused IgG1 mAb showed 235 
the classical circulation profile in both groups of macaques (Figure 5A) following virus 236 
challenge.  RMs of Group B cleared IgG1 faster compared with animals of Group A 237 
(Figure 5B).  Mean half-lives of HGN194 IgG1 were calculated at 15.8 ± 3.9 days for 238 
Group A and 8.2 ± 2.6 days for Group B RMs (P = 0.0087, Mann-Whitney test). 239 
Although HGN194 IgG1 demonstrated shorter half-life in Group B RMs, mAb 240 
concentrations on the day 0, the day of virus challenge, were similar for Groups A and B 241 
animals (Table 2).  These concentrations were comparable to that reported previously 242 
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[23] as well as to the IgG1 concentration observed during the previous experiment 243 
(unpublished data).  Mean HGN194 IgG1 concentrations were 3.3 ± 0.9 µg/ml for Group 244 
A and 3.1 ± 0.5 µg/ml for Group B, respectively.   245 
Plasma samples of Group A and B RMs collected on the day of virus challenge 246 
were able to neutralize SHIV-1157ipEL-p, the challenge virus, with the same efficiency 247 
as demonstrated by TZM-bl cell-based neutralization assays (Table 2).  There was no 248 
difference between mean 50% plasma inhibitory concentration (IC50) values of Groups 249 
A (0.5 ± 0.2 µg/ml) and B (0.4 ± 0.08 µg/ml) measured in RM plasmas on the day of 250 
virus challenge.  These results are in line with in vivo IC50 values observed previously 251 
for HGN194 IgG administered to infant RMs at 1 mg/kg dose [23].  Also, these data 252 
clearly demonstrate that, in spite of faster clearance of mAb by RMs of Group B, RMs of 253 
Groups A and B maintained equal concentrations of IgG1 in plasma on the day of SHIV-254 
1157ipEL-p challenge and that mAb was able to neutralize the challenge virus with the 255 
same efficiency.  Of note, all RMs in Group B with the shorter half-life were viremic, 256 
which probably resulted in faster clearance post-challenge due to immune complex 257 
formation. 258 
 259 
Individual mAbs and combination of IgG1+dIgA2 show the same neutralization 260 
profiles in vitro 261 
To understand why the combination was more protective than treatment with individual 262 
mAbs, we examined the neutralization of the challenge virus in vitro by the combination 263 
of IgG1+dIgA2.  Toward this end, we used TZM-bl, A3R5 and human peripheral blood 264 
mononuclear cell (PBMC)-based assays (Figure 6A-C).  For all three assays, the 265 
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differences between neutralization curves were not significant as evaluated by multiple 266 
t-tests and two-way ANOVA test for multiple comparisons (not shown).   267 
It should be noted that in the neutralization assays, dIgA2 and IgG1 were used at 268 
the same mass concentrations. The concentration of the IgG+dIgA2 combination was 269 
the sum of mass concentrations of individual mAbs.  Dimeric IgA2 has a molecular 270 
weight of ~315 kDa, compared to ~150 kDa for IgG1; thus, the molar concentration of 271 
dIgA2 taken at the same mass concentration as IgG1 is twofold lower than for IgG1.  272 
However, dIgA2 bears four Fab regions, and IgG1 has only two.  Therefore, the dIgA2 273 
solution with a twofold lower molar concentration than the IgG1 solution contained the 274 
same molar concentration of antigen combining sites as the IgG1 solution.  These 275 
considerations explain the similar neutralization curves for HGN194 IgG1, dIgA2, and 276 
combination of both. 277 
 278 
The combination of IgG1+dIgA2 does not inhibit virus transcytosis in vitro 279 
As we previously reported [20], only HGN194 dIgA1, but not dIgA2 or IgG1 as single 280 
agent, was able to inhibit virus transcytosis in vitro.  We evaluated whether the 281 
combination of HGN194 IgG1+dIgA2 could inhibit the transcytosis of SHIV-1157ipEL-p 282 
at pH 6.  A low pH has been reported to enhance antibody-mediated virus transcytosis 283 
[26].  Additionally, the pH of colonic rectal fluid for Macaca species was reported to 284 
range between 5.1 and 7.8 [27, 28].  As shown, the mean concentration of dIgA2 285 
administered i.r. was 231.6 µg/ml 30 min after topical application [20].  To reflect the in 286 
vivo observed concentration of dIgA2, we performed the transcytosis assay at 200 287 
µg/ml of dIgA2 or dIgA1 used as a positive control mixed with different concentrations of 288 
 15 
HGN194 IgG1 or the isotype control IgG1 Fm-6 (Figure 6D).  At pH 6, HGN194 IgG1 289 
alone or in combination with dIgA2 enhanced transcytosis of SHIV-1157ipEL-p across 290 
HEC-1A cells.  As expected, dIgA1 used as a positive control completely reversed the 291 
effect of specific IgG1 and inhibited transcytosis almost completely at any IgG1 292 
concentration tested.  The fact that the IgG1+dIgA2 combination was unable to prevent 293 
enhanced virus transcytosis in vitro suggests that this combination is not likely to exert 294 
its protective effect through inhibition of transcytosis.   295 
 296 
Discussion 297 
We have shown that HIV-1 Env-specific IgG1 plasma Abs in combination with mucosal 298 
dIgA2 of the same epitope specificity completely protected RMs against high-dose 299 
mucosal challenge with SHIV-1157ipEL-p.  Initially, we demonstrated that RMs that had 300 
remained aviremic in previous passive immunization experiments had developed low-301 
level, virus-specific cell-mediated immune responses and thus represent a relevant 302 
model to assess immunization efficacy among HIV-1-exposed, uninfected individuals.  303 
The striking 100% protection we observed here in RMs with the combination of i.v. IgG1 304 
plus i.r. dIgA2 mAbs was unexpected – given that the group treated with the IgG1 305 
version alone had 0% protection and that i.r. dIgA2 had protected only 17% of RMs 306 
challenged with the same clade C SHIV earlier.  Lastly, we demonstrated that inhibition 307 
of virus transcytosis, as suggested for dIgA1 [20], was unlikely to be the mechanism of 308 
protection by the combination of IgG1+dIgA2.  Thus, our findings suggest that mucosal 309 
dimeric IgA2, if generated by active immunization, will complement HIV-1-specific 310 
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plasma IgG1 in preventing virus acquisition rather than diminishing the protective role of 311 
plasma IgG1.   312 
The gastrointestinal mucosa is the largest mucosal surface in the human body, 313 
and it represents the major portal of HIV-1 entry during mother-to-child transmission via 314 
breastfeeding, sexual transmission in men who have sex with men, as well as during 315 
heterosexual anal intercourse [reviewed [29]].  The risk of HIV-1 transmission through 316 
receptive anal sex was estimated by meta-analysis at 1.4% (an average of one 317 
transmission event occurred for every 71 exposures), which is at least 10 times higher 318 
than for unprotected vaginal intercourse [reviewed [30]].  On another note, the 319 
distribution of IgG and IgA varies considerably between different body compartments 320 
[31].  While serum contains 3.5 – 14 times more IgG than IgA, IgAs are more prevalent 321 
in gastrointestinal tract secretions. Within the intestine, secretions of the digestive part 322 
contain more IgA1 than IgA2, whereas secretions of the colon generally possess slightly 323 
more IgA2 than IgA1 [31].  In the current study, IgG1 was administered i.v. and thus 324 
was distributed systemically as well as into some mucosal fluids.  After topical 325 
administration, dIgA2 remained localized at the rectal mucosa, because there is no IgA 326 
back-transfer from the intestinal lumen across the epithelial barrier.  In contrast, the Fc 327 
neonatal receptor (FcRn) can shuttle IgG in both directions; it unloads IgG or IgG-328 
immune complex cargo in a pH-dependent manner [reviewed in [32]].  Thus, our 329 
passive immunization study reflected the compartmentalization of Ab responses and 330 
addressed the vulnerability of the rectal mucosa for HIV-1 infection.  331 
While a negative correlation was established between circulating anti-HIV-1 Env 332 
IgA in the RV144 trial, our data strongly suggest that a successful HIV-1 vaccine must 333 
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generate both mucosal IgA and systemic IgG responses.  Such a defensive strategy is 334 
best described by the military term “defense-in-depth” – an approach to defend a vital 335 
core by pre-planned, well-armed, multiple lines of defense that can provide backup in 336 
case the frontline is breached.  Defense-in-depth against mucosal HIV-1 transmission 337 
can be described as follows.  When HIV-1 virions first encounter mucus in the mucosal 338 
cavity, they are exposed to secretory IgAs (SIgAs), which may either crosslink the 339 
virions, prevent virus transcytosis across the epithelial barrier, or simply neutralize virus.  340 
In case some virions remain free, they can penetrate the mucus and the epithelium by 341 
transcytosis or other mechanism.  Such virions then face ubiquitous IgG and may be 342 
neutralized by it.  The neutralization capacity of antiviral IgG is limited by its affinity and 343 
by the accessibility of HIV-1 Env epitopes.  In other words, the tissue and/or plasma 344 
concentration of neutralizing IgG must be high enough to neutralize incoming virus as it 345 
penetrates the mucosa.   346 
In our current study, the concentration of HGN194 IgG1 used for i.v. 347 
administration (1.45 mg/kg) was expected to protect approximately half of the RMs from 348 
SHIV challenge based on data from our previous study, where 50% of RMs were 349 
protected with 1 mg/kg of HGN194 IgG1 [23].  However, the RMs used for the current 350 
study had developed low-level cellular immune responses as a consequence of their 351 
earlier experience to live virus; in fact, proliferative responses among CD4+ lymphocytes 352 
tended to predominate.  Thus, the HGN194 IgG1 dose of 1.45 mg/kg was not protective 353 
and all the animals of Group B became infected.  When applied mucosally (i.r.) as 354 
single mAbs in an earlier study [20], IgG1 protected only 33% and dIgA2 17% of RMs, 355 
respectively against the same challenge virus.  However in the current experiment, the 356 
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combination of i.v. IgG1 plus i.r. dIgA2, in which both mAbs were administered at sub-357 
protective doses, completely prevented virus acquisition.  It is reasonable to suggest 358 
that in this case, part of the challenge virus was neutralized in the rectal lumen by dIgA2 359 
and to a lesser extent by transudated IgG1; the residual virus, which was not 360 
neutralized in the lumen and crossed the epithelium, was met and neutralized by IgG1 361 
in tissues or in the circulation.  Thus, our RM model of passive immunization with the 362 
combination of topically applied dIgA2 and systemically administered IgG1 followed by 363 
mucosal SHIV challenge reflects the outcome of a successful HIV-1 vaccine that 364 
induces both systemic IgG and mucosal IgA responses.  Our current study provides 365 
proof-of-concept for the defense-in-depth strategy against mucosal transmission of HIV-366 
1. 367 
The results of the current study, taken together with our previous findings 368 
regarding the protective role of dIgA1 [20], provide a rational explanation of a possible 369 
way of preventing HIV-1 acquisition if active vaccination were to generate both mucosal 370 
IgA and systemic antibody responses.  In this regard, to achieve the complete 371 
prevention of HIV-1 infection, a successful vaccine must induce different immune 372 
effectors, including HIV-1 Env-specific Abs in mucosal secretions as frontline defense, 373 
with back-up provided by neutralizing Abs in tissues and in the circulation and cytotoxic 374 
T cells, thus generating defense-in-depth.  375 
 376 
 377 
 378 
 379 
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Conclusions 380 
Passive immunization with mAb HGN194 IgG1 given systemically together with 381 
HGN194 dIgA2 given mucosally completely protected all RMs from high-dose mucosal 382 
SHIV challenge, while no monkey given the IgG1 mAb i.v. alone was protected.   383 
These results together with our previous findings regarding the protective role of 384 
mucosal dIgA1 [20] provide proof-of-concept for defense-in-depth against mucosal 385 
transmission of HIV-1. 386 
 387 
Materials and Methods 388 
Cell lines, reagents, and virus 389 
The following reagent was obtained through the NIH AIDS Reagent Program, Division 390 
of AIDS, NIAID, NIH: TZM-bl from Dr. John C. Kappes, Dr. Xiaoyun Wu and Tranzyme 391 
Inc..  A3R5 cells were kindly provided by Dr. David Montefiori. MAb Fm-6 and VRC01 392 
were kindly provided by Drs. Wayne Marasco (Dana-Farber Cancer Institute) and John 393 
Mascola (Vaccine Research Center, NIH), respectively. The SHIV-1157ipEL-p stock 394 
(grown in RM PBMC) had a p27 concentration of 792 ng/ml and 7.8 x 105 50% tissue 395 
culture infectious doses (TCID50)/ml as measured in TZM-bl cells. Recombinant 396 
HGN194 mAb forms were prepared as described previously [20]. 397 
 398 
Lymphocyte proliferation assay 399 
PBMC were stained with CFSE (CellTraceTM CFSE Cell Proliferation Kit, Invitrogen) 400 
and incubated with or without SIVmac239 Gag peptides (2 µg/ml for each peptide).  The 401 
peptides (obtained through ARRRP) were 15-mers with an 11-amino acid overlap 402 
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between sequential peptides and represented the complete protein sequence.  Cells 403 
without any stimuli were used to determine background proliferation.  After incubation 404 
for 5 days at 37oC, cells were stained with anti-CD3-Alexa Fluor 700 (clone SP34-2), 405 
anti-CD4-PerCP (clone L200), and anti-CD8-PE (clone RPA-T8) Abs (all from BD 406 
Pharmingen).  After fixation, at least 10,000 CD3+ cells were acquired by flow 407 
cytometry, and data were analyzed using FACSDiva (BD Biosciences) software.  The 408 
percentages of proliferating CD3+CD4+ and CD3+CD8+ cells were determined by CFSE 409 
dilution; background proliferation (without stimulation) was subtracted. 410 
 411 
ELISAs 412 
To evaluate HGN194 IgG1 pharmacokinetics, ELISA plates (Nunc) were coated with 1 413 
µg/ml of SHIV-1157ip gp120 in PBS.  After washing, plates were blocked with 4% Non-414 
fat dry milk (Bio-Rad), 0.05% Tween-PBS (blocking buffer).  Plates were then incubated 415 
with serial dilutions of RM plasma samples in triplicates.  HGN194 IgG1 was included as 416 
a standard ranging from 0.1 to 31 ng/ml.  After washing, plates were developed by 417 
incubation for 1 h with goat anti-human IgG HRP-conjugated Ab (Jackson 418 
Immunoresearch) or goat anti-human HRP-conjugated Ab that had been adsorbed with 419 
monkey IgG (Southern Biotech) to avoid cross-reactivity with monkey anti-gp120 Abs.  420 
Color reaction was performed with TMB solution (Life Technologies). 421 
Analysis of RM plasma binding to SHIV-1157ip gp120 was done essentially as 422 
described above. Plates were coated with gp120, blocked and incubated with RM 423 
plasma samples at different dilutions.  To detect binding, plates were incubated with 424 
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mouse monoclonal anti-monkey IgG HRP-conjugated Ab with no cross-reactivity to 425 
human IgG (Southern Biotech) and developed with TMB solution. 426 
To evaluate RM anti-human IgG responses, plates were coated with 1 µg/ml of 427 
HGN194 IgG1 in carbonate buffer, pH 9.6. After blocking and incubation with RM 428 
plasma samples, plates were probed mouse monoclonal anti-monkey IgG HRP-429 
conjugated Ab with no cross-reactivity to human IgG (Southern Biotech) and developed 430 
with TMB solution. 431 
 432 
Animals 433 
RMs were housed at the Yerkes National Primate Research Center (YNPRC, Atlanta, 434 
GA) in accordance with standards of the National Institutes of Health Guide for the Care 435 
and Use of Laboratory Animals.  Animal experiments were approved by the Institutional 436 
Animal Care and Use Committees at Emory University and the Dana-Farber Cancer 437 
Institute (DFCI) via a Collaborating Institution Animal Use Agreement.  Blood was 438 
collected under ketamine or Telazol anesthesia.  439 
 440 
Passive immunization and mucosal SHIV-1157ipEL-p challenge 441 
All RMs were Mamu B*008 and B*017 negative and aged between 12 to 16 months at 442 
the time of challenge.  Mamu A*001-positive animals were evenly distributed in each 443 
group, as were RMs with different FcγRIIIa genotypes (Table 1).  As depicted on Figure 444 
3, Group A RMs (n=6) were treated i.v. with 1.45 mg/kg of HGN194 IgG1 at –24 h, and 445 
i.r. with 1.25 mg (in 2.1 ml of PBS) of HGN194 dIgA2 30 min before challenge.  The six 446 
macaques of Group B were treated i.v. with 1.45 mg/kg of HGN194 IgG1 only at –24 h.  447 
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The control Group C consisted of two untreated animals.  All monkeys were challenged 448 
i.r. with 31.5 50% AID50 of SHIV-1157ipEL-p [24].  449 
 450 
Plasma viral RNA levels 451 
Plasma viral RNA levels were measured as described [25, 33]. 452 
 453 
In vitro neutralization assays 454 
For all the assays, mAbs were incubated with virus for 1 h at 37°C and then the cells 455 
were added to the mixture.  The TZM-bl assay was performed as described [34]. In 456 
brief, virus was added to cells in the presence of DEAE-dextran (Sigma), washed 1x on 457 
day 1 and luminescence was measured on day 2 using luciferase substrate Bright-Glo 458 
(Promega).  The A3R5 cell-based assay was performed as described [35] with 459 
NL.LucR-1157ipEL virus encoding the env gene of SHIV-1157ip-EL envelope [36] and 460 
Renilla luciferase [37].  Human PBMC-based assays were performed as described [23].   461 
 462 
Inhibition of transcytosis  463 
HEC-1A cell (ATCC) monolayers were created on 0.4 µm polyethylene terephthalate 464 
(PET) membrane hanging transwell inserts (Millipore).  Electrical resistance of >400 465 
mOhms/cm2 across the membrane confirmed monolayer integrity. Cell-free SHIV-466 
1157ipEL-p (2 ng/ml of p27) was preincubated for 1 h at 37ºC alone or with various 467 
concentrations of HGN194 dIgA1, HGN194 dIgA2, or IgG1, or control IgG1 Fm-6.  Next, 468 
virus or vius/mAb mixtures were added to the apical surface of the cell monolayer in the 469 
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upper chamber.  After 12 h, fluid in the lower chamber (“subnatant fluid”) was collected 470 
and used to measure viral RNA copy numbers by RT-PCR [25, 33].   471 
 472 
Statistical Analysis 473 
Statistical analyses were performed using Graph Pad Prism for Windows, version 6 474 
(Graph Pad Software Inc., San Diego, CA).  475 
 476 
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Table 1 Group reassignment of virus-experienced uninfected RMs 659 
Groups Animal HGN194 version 
Type of 
previous 
mAb 
treatment 
MHC allele TRIM5α 
genotype 
restriction 
Reference 
A*001 B*008 B*017 
Group A RBk-14 IgG1wt i.v. - - - moderate - 
IgG1+dIgA2 RIr-14 IgG1kif i.v. - - - high - 
 
RKv-14 IgG1wt i.r. - - - high [20] 
 
RLz-14 dIgA1 i.r. - - - high [20] 
 
RNv-14 dIgA1 i.r. + - - moderate [20] 
 
RWw-14 dIgA1 i.r. - - - high [20] 
Group B RAy-14 dIgA1 i.r. - - - moderate [20] 
IgG1 RCw-14 IgG1wt i.r. - - - moderate [20] 
 
RIk-14 IgG1wt i.v. + - - moderate - 
 
ROw-14 dIgA1 i.r. - - - high [20] 
 
RUq-14 IgG1kif i.v. - - - high - 
 
RYv-14 dIgA2 i.r. - - - high [20] 
Group C REo-14 IgG1wt i.v. + - - moderate - 
controls RIm-14 IgG1kif i.v. - - - moderate - 
All RMs had no anti-HIV Env Ab responses at the time of the 2nd virus challenge. IgG1wt, 660 
wild type of HGN194 IgG1; IgG1kif, afucosylated version of HGN194 IgG1. 661 
  662 
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Table 2 Concentration and IC50 of HGN194 IgG1 in RM plasma on the day of virus 663 
challenge 664 
Groups 
Animal 
# 
IgG1 
concentration, 
µg/ml 
Plasma 
IC50, µg/ml 
Group A RBk-14 4.0 0.54 
IgG1+dIgA2 RIr-14 2.5 ND 
 
RKv-14 2.8 ND 
 
RLz-14 2.5 0.32 
 
RNv-14 3.2 0.86 
 
RWw-14 4.9 0.30 
Group B RAy-14 3.5 0.53 
IgG1 RCw-14 2.4 0.41 
 
RIk-14 3.9 ND 
 
ROw-14 3.6 0.56 
 
RUq-14 3.2 0.40 
 
RYv-14 2.6 0.32 
 665 
Plasma IC50 concentrations were determined using the concentration of mAb in RM 666 
plasma on the day of challenge and the dilution of this plasma sample showing 50% of 667 
neutralization in TZM-bl cell assay. Calculations were performed in respect of 668 
neutralization obtained with the plasma sample from the same RM taken before the 669 
mAb administration at the same dilution.  ND, not determined. Experiment performed in 670 
triplicate. 671 
  672 
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Figure legends 673 
Figure 1 Antiviral T-cell responses after previous SHIV-1157ipEL-p challenge [20].  674 
PBMC were stimulated with overlapping peptides representing SIVmac239 Gag and 675 
proliferation of CD4+ and CD8+ cells was measured using the CFSE dilution method as 676 
described in Materials and Methods.  The y-axis indicates % proliferating cells.  PBMC 677 
isolated from two naïve macaques (RCy-5 and RSf-12) were used as a negative control 678 
and PBMC from a previously vaccinated, aviremic animal RAt-9 [38] served as a 679 
positive control, respectively.  Panel A. Positive (RAt-9) [38] and negative (RCy-5 and 680 
RSf-12) controls.  Panel B. T-cell responses of RMs that had received wild-type 681 
(IgG1wt) or afucosylated (IgG1kif) versions of HGN194 IgG1 systemically (i.v.) 682 
(unpublished data).  Panel C. T-cell responses of animals that had previously received 683 
HGN194 IgG1, dimeric IgA1 or dimeric IgA2 topically (i.r.) [20].  684 
 685 
Figure 2 Antibody responses in RMs previously given passive immunization with 686 
different forms of HGN194 [20].  Panels A and B, Only animals that had received 687 
HGN194 systemically were analyzed.  Mucosally treated RMs had been tested earlier 688 
and HGN194 had not been detected in the plasma (data not shown).  Red bars, RMs 689 
assigned to Group A of the current study; blue bars, RMs assigned to Group B; black 690 
bars, RMs assigned to Group C.  Solid bars show recipients of HGN194 IgG1wt and 691 
striped bars depict recipients of IgGkif.  Panel A.  Residual concentration of HGN194 692 
IgG1 at different time points after administration.  HGN194 IgG1 was used as a 693 
standard.  Secondary goat anti-monkey HRP-conjugated Ab was RM IgG adsorbed. 694 
Panel B. RM anti-human IgG responses at different time points after HGN194 IgG1 i.v. 695 
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administration.  Grey bars, goat anti-human Ab served as a positive control; +C, positive 696 
control (goat anti-human Ab HRP-conjugated).  Panels C and D.  HIV Env binding 697 
ELISA analysis of RM plasma samples collected at different time points after virus 698 
challenge.  Panel D. Blue, Group B RM plasma samples.  SHIV-1157ip gp120 served 699 
as antigen. Panel C. Red, Group A RM plasma samples.  Open bars, pooled naïve RM 700 
plasma was used as a negative control; grey bars, plasma of RRi-11 [39] was used as 701 
positive control.  The secondary Ab was mouse anti-monkey HRP-conjugated 702 
secondary Ab with minimal cross-reactivity to human IgG.  703 
 704 
Figure 3 Study timeline and design.  Three groups of RMs were enrolled.  Group A (n 705 
= 6) received the combination of i.v. HGN194 IgG1 (1.45 mg/kg); and i.r. HGN194 dIgA2 706 
(1.25 mg).  Group B RMs (n = 6) received i.v. HGN194 IgG1 (1.45 mg/kg) only.  Group 707 
C (n = 2) RMs served as virus-only controls.  Black arrow, mAb administrations; yellow 708 
arrow, 24 h after IgG1 administration and 30 min after dIgA2 topical application, if any, 709 
animals were challenged i.r. with 31.5 AID50 of SHIV-1157ipEL-p.   710 
 711 
Figure 4  The combination of HGN194 IgG1+dIgA2 completely protects RMs from 712 
high-dose mucosal virus challenge.  A. Red, viral RNA loads for individual RMs for 713 
Group A (IgG1+dIgA2); blue, vRNA loads for Group B (IgG1) RMs; black, vRNA loads 714 
for Group C (controls) RMs.  B. Kaplan-Meier analysis of time until vRNA load 715 
exceeded 50 copies/ml. Log rank test significance P value is indicated.  Red, Group A; 716 
blue, Group B.   717 
 718 
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Figure 5 Analysis of HGN194 IgG1 levels in plasma.  Panel A. HGN194 IgG1 719 
pharmacokinetics in RM groups. Black arrow indicates SHIV-1157ipEL-p challenge; red, 720 
RM of Group A; blue, RMs of Group B.  Panel B.  Analysis of HGN194 IgG1 half-life in 721 
RMs.  Red, RMs of Group A; blue, RMs of Group B.  Statistical analysis was performed 722 
by Mann-Whitney test (P < 0.05). 723 
 724 
Figure 6 The combination of HGN194 IgG1+dIgA2 neutralizes virus similarly to the 725 
individual mAbs and does not inhibit virus transcytosis.  A-C. Neutralization of 726 
SHIV-1157ipEL-p by HGN194 IgG1, dIgA2 and combination of both. The concentration 727 
of IgG1+dIgA2 combination is the sum of concentrations of individual mAbs.  MAbs 728 
VRC01 and Fm-6 were used as positive and negative controls, respectively (not 729 
shown).  A. Human PBMC-based assay; B. TZM-bl cell assay; and C. A3R5 cell assay. 730 
D. Inhibition of transcytosis.  Solid lines, HGN194 IgG1; dashed lines, isotype control 731 
mAb Fm-6.  Both IgG1 Abs ranging from 1 to 100 µg/ml were incubated with the virus 732 
alone (blue, HGN194; light blue, Fm-6), or together with 200 µg/ml of dIgA2 (red, 733 
HGN194; light red, Fm-6), positive control dIgA1 (grey, HGN194; light grey, Fm-6).  734 
Next, virus or virus/mAb mixtures were added to the HEC-1A cell monolayer.  Twelve h 735 
later, vRNA copy numbers were measured. Percent of transcytosis inhibition was 736 
calculated in comparison with the number of vRNA copies determined for wells with 737 
virus alone.  Negative values on Y axis show percent transcytosis enhancement.  All 738 
experiments were repeated at least twice. 739 
 740 
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